Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Langsigtet sikkerhed og effekt af Odevixibat hos patienter med Alagille syndrom (ASSERT-EXT)

20. oktober 2026 opdateret af: Albireo, an Ipsen Company

En åben-label undersøgelse til evaluering af den langsigtede sikkerhed og effektivitet af Odevixibat (A4250) hos patienter med Alagille syndrom (ASSERT-EXT)

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS).

The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis).

The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This Phase 3, open-label, multi-center extension study will have two groups of participants: Cohort 1 (participants who participated in Study A4250-012 [NCT04674761; ASSERT] and meet the entry criteria for this study) and Cohort 2 (infants under 12 months of age) with ALGS.

The study will consist of 2 or 3 periods:

  1. A 'Treatment period' of 72 weeks (cohort 1) or 12 weeks (cohort 2). Participants will visit the clinic every 4 to 12 weeks and will receive a dose of 120 μg/kg odevixibat daily.
  2. An 'Optional extension period' where participants who wish to continue receiving odevixibat after the 'treatment period' will have the opportunity to remain on treatment with visits every 16 weeks until the drug is commercially available. The optional extension is available provided continued use is supported by the risk-benefit profile, the participant has not been previously withdrawn or discontinued from the study, and the study is not terminated by the Sponsor.
  3. A 'Safety follow-up period' of 4 weeks (cohort 1) or 2 weeks (cohort 2). The Safety Follow-up Period will not occur for those who remain on treatment in the optional extension period.

Participants will need to complete an e-diary and questionnaires throughout the study (cohort 1 only). Participants will undergo blood samplings, urine collections (cohort 1 only), physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

62

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Brussels, Belgien, 1200
        • Cliniques Universitaires Saint-Luc Bruxelles
      • Birmingham, Det Forenede Kongerige
        • Birmingham Women's and Children's NHS Foundation Trust
      • London, Det Forenede Kongerige, SE5 9RS
        • King's College Hospital NHS Foundation Trust King's College Hospital Paediatric Research
    • California
      • San Diego, California, Forenede Stater, 92123
        • Rady Children's Hospital
      • San Francisco, California, Forenede Stater, 94158
        • UCSF
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30329
        • Children's Healthcare of Atlanta
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Riley Hospital for Children at IU Health
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
        • Boston Children's Hospital
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64018
        • Children's Mercy Hospital and Clinics
    • New York
      • New Hyde Park, New York, Forenede Stater, 11042
        • Northwell Health System
      • New York, New York, Forenede Stater, 10016
        • Hassenfeld Children's Hospital at NYU Langone
      • New York, New York, Forenede Stater, 10032
        • New York-Presbyterian / Columbia University Irving Medical Center
      • The Bronx, New York, Forenede Stater, 10467
        • The Childrens Hospital at Montefiore Albert Einstein School of Medicine
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27710
        • Atrium Health Carolinas Medical
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45229
        • Cincinnati Children's Hospital
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Oregon Health Science University School of Medicine
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37232
        • Monroe Carell Jr. Childrens Hospital at Vanderbilt
    • Texas
      • Dallas, Texas, Forenede Stater, 75207
        • Childrens Medical Center of Dallas University of Texas Southwestern
      • Houston, Texas, Forenede Stater, 77030
        • Texas Children's Hospital
      • San Antonio, Texas, Forenede Stater, 78215
        • Texas Liver Institute
      • Bron, Frankrig, 69677
        • Hôpital Femme Mère Enfant de Lyon
      • Lille, Frankrig
        • Antenne pediatrique du CIC-Hopital Jeanne De Flandre
      • Paris, Frankrig, 75015
        • Hopital Necker Enfants Malades
      • Groningen, Holland, 9713 GZ
        • Universitair Medisch Centrum Groningen
      • Utrecht, Holland
        • Wilhelmina Children's Hospital UMCU Utrecht
      • Florence, Italien
        • AOU Meyer
      • Padova, Italien, 35128
        • Azienda Ospedale University
      • Rome, Italien, 00165
        • Ospedale Pediatrico Bambino Gesu
      • Kuala Lumpur, Malaysia, 59100
        • University of Malaya Medical Center
      • Warsaw, Polen, 04-730
        • Instytut Pomnik-Centrum Zdrowia Dzieck
      • Istanbul, Tyrkiet (Türkiye)
        • Istanbul University Istanbul Medical Faculty Hospital
      • Berlin, Tyskland, 13353
        • Charité - Universitätsmedizin Berlin
      • Hanover, Tyskland, 30625
        • Medizinische Hochschul
      • Tübingen, Tyskland, 72076
        • Universitatsklinik fur Kinder-und Jugendmedizin Tubingen

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Cohort 1 :

  1. Completion of the 24-week Treatment Period of Study A4250-012
  2. Signed informed consent and assent as appropriate. Patients who turn 18 years of age (or legal age per country) during the study will be required to re-consent to remain on the study
  3. Caregivers (and age-appropriate patients) must be willing and able to use an electronic diary (eDiary) device as required by the study
  4. Sexually active males and females must agree to use a reliable contraceptive method with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or complete abstinence) from signed informed consent through 90 days after last dose of study drug.

Cohort 2 :

  1. Infant with clinically confirmed ALGS , ≤11 months of age at Study Day 1
  2. Body weight ≥2 kg at Study Day 1
  3. Gestational age ≥36 weeks. For children born with gestational age between 32 and 36 weeks, a postmenstrual age of ≥36 weeks is required .
  4. Signed parent/legal guardian informed consent.

Exclusion Criteria:

Cohort 1 :

  1. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
  2. Patients who were not compliant with study drug treatment or procedures in Study A4250-012
  3. Any other conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
  4. Known hypersensitivity to any components of odevixibat

Cohort 2 :

  1. Patient with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:

    1. Biliary atresia of any kind
    2. Progressive familial intrahepatic cholestasis (PFIC)
    3. Benign recurrent intrahepatic cholestasis
  2. Patient with a past medical history or ongoing presence of any other disease or condition known to interfere with the absorption, distribution, metabolism (specifically bile acid metabolism), or excretion of drugs in the intestine, including but not limited to, inflammatory bowel disease

  3. Patient with past medical history or ongoing chronic diarrhea requiring intravenous fluid or nutritional intervention for treatment of the diarrhea and/or its sequelae

  4. Patient has a confirmed past diagnosis of infection with human immunodeficiency virus or other present and active, clinically significant chronic infection

  5. Recent infection requiring hospitalization or treatment with parenteral anti-infective within 4 weeks of Study Day 1 or completion of oral anti-infective treatment within 2 weeks prior to the Screening Visit

  6. Cancer diagnosis (except for basal cell carcinoma)

  7. Chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m2

  8. Patient with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to the Screening Visit

  9. Patient has had a liver transplant, or a liver transplant is planned within 6 months of Study Day 1

  10. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy

  11. International normalized ratio (INR) >1.4 (the patient may be treated with Vitamin K, and if INR is ≤1.4 at resampling the patient may be enrolled)

  12. Serum alanine aminotransferase (ALT) >10 × upper limit of normal (ULN) at Screening

  13. Serum ALT >15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation

  14. Total bilirubin >15 × ULN at Screening

  15. Patient suffers from uncontrolled, recalcitrant pruritic condition other than ALGS. Examples include, but not limited to, refractory atopic dermatitis or other primary pruritic skin diseases.

  16. Patient exposed to alcohol or substance abuse in utero

  17. Bile acid or lipid binding resins and medications that slow gastrointestinal motility

  18. Patient has had investigational exposure to a drug, biologic agent, or medical device within 30 days prior to the Screening Visit, or 5 half-lives of the study agent, whichever is longer

  19. Any other conditions or abnormalities which, in the opinion of the investigator may compromise the safety of the patient, or interfere with the patient participating in or completing the study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Odevixibat (A4250)

Capsules for oral administration once daily for 72 weeks.

Odevixibat is a small molecule and selective inhibitor of IBAT.

Andre navne:
  • A4250

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ændring fra baseline ved samtidig medicinering.
Tidsramme: Baseline til uge 12 (kohorte 2).
Baseline til uge 12 (kohorte 2).
Ændring fra baseline i fedtopløselige vitaminniveauer.
Tidsramme: Baseline til uge 12 (kohorte 2).
Baseline til uge 12 (kohorte 2).
Change from baseline in pruritus
Tidsramme: Baseline to week 72 (cohort 1).

Assessed as change in scratching score as measured by measured by the Albireo Observer-Reported Outcome Caregiver Instrument.

Baseline to week 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Tidsramme: Baseline to week 12 (cohort 2).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that results in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Physical Examination
Tidsramme: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes in Laboratory Parameters
Tidsramme: Baseline to week 12 (cohort 2).

The following laboratory parameters will be reported: blood chemistry, hematology and coagulation. The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Vital Signs.
Tidsramme: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ændring fra baseline i serumgaldesyreniveauer
Tidsramme: Baseline til uge 72 (kohorte 1).
Baseline til uge 72 (kohorte 1).
Ændring fra baseline i serumgaldesyreniveauer.
Tidsramme: Baseline til og med uge 72 (kohorte 1).
Baseline til og med uge 72 (kohorte 1).
Antal deltagere med ændring fra baseline i fysisk undersøgelse
Tidsramme: Baseline til uge 72 (kohorte 1).
Baseline til uge 72 (kohorte 1).
Antal deltagere med ændring fra baseline i vitale tegn
Tidsramme: Baseline til uge 72 (kohorte 1).
Baseline til uge 72 (kohorte 1).
Ændring fra baseline ved samtidig medicinering
Tidsramme: Baseline til uge 72 (kohorte 1).
Baseline til uge 72 (kohorte 1).
Ændring fra baseline i laboratorietestresultater Farmakokinetisk (PK) Cmax [Tidsramme: Dag 1, Uge 4, Uge 8 og Uge 12]
Tidsramme: Baseline til uge 72 (kohorte 1).
Baseline til uge 72 (kohorte 1).
Ændring fra baseline i plasmakoncentration af undersøgelseslægemidlet
Tidsramme: Dag 1, uge ​​4, uge ​​8 og uge 12 (kohorte 1).
Dag 1, uge ​​4, uge ​​8 og uge 12 (kohorte 1).
Farmakodynamiske parametre: Ændring i serumgaldesyreniveauer
Tidsramme: Baseline til uge 12 (kohorte 2).
Baseline til uge 12 (kohorte 2).
Change from baseline in patient reported and observer reported itching and scratching severity scores
Tidsramme: Baseline to week 72 (cohort 1).

Assessed by the the Albireo ObsRO/ Patient Reported Outcomes (PRO) instruments. The Albireo ObsRO/PRO scratching and itch severity items use 0 to 4 response scales, where each response is distinguished by a unique facial expression, verbal anchor, number, and color code.

Baseline to week 72 (cohort 1).
Percentage of participants achieving a clinically meaningful decrease in pruritus (pruritus responders)
Tidsramme: Baseline to week 72 (cohort 1).

Assessed by the Albireo ObsRO/patient reported outcomes (PRO) instruments

Baseline to week 72 (cohort 1).
Change from baseline in sleep parameters.
Tidsramme: Baseline to week 72 (cohort 1).

Assessed with the Albireo ObsRO/PRO instruments (e.g: tiredness and number of awakenings).

Baseline to week 72 (cohort 1).
Change from baseline in Pediatric Quality of Life Inventory (PedsQL) scores.
Tidsramme: Baseline to week 72 (cohort 1).

The PedsQL instrument consists of 36 questions and uses a 5-point response scales, where higher scores indicates worst symptoms.

Baseline to week 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Patient Global Impression of Improvement (PGIC) score.
Tidsramme: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Clinical Global Impression of Improvement (CGIC) score.
Tidsramme: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Clinical Global Impression of Change (CGIC) is a clinician-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Caregiver Global Impression of Change (CaGIC) score
Tidsramme: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The caregiver Global Impression of Change is a caregiver-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Tidsramme: Baseline to week 72 (cohort 1).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that resultes in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 72 (cohort 1).

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Ipsen Medical Director, Ipsen

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. september 2021

Primær færdiggørelse (Anslået)

15. februar 2027

Studieafslutning (Anslået)

15. februar 2027

Datoer for studieregistrering

Først indsendt

13. august 2021

Først indsendt, der opfyldte QC-kriterier

1. september 2021

Først opslået (Faktiske)

5. september 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD-delingstidsramme

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

IPD-delingsadgangskriterier

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner